Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium.
1. The endothelium is critical in the control of vascular haemodynamics and haemostasis. Endothelial dysfunction, typically characterized by decreased nitric oxide bioavailability and response to endothelium-dependent agonists, is well accepted as a defining characteristic of early atherosclerosis. 2. Numerous epidemiological studies have reported that increased levels of circulating HDL are vasculoprotective and reduce the incidence of adverse cardiovascular events. Traditionally, these effects have been attributed to the ability of HDL to remove cholesterol from cells via reverse cholesterol transport. However, there is increasing evidence that the beneficial effects on the endothelium by HDL encompass its anti-inflammatory, antithrombotic and anti-oxidative properties, which include the release of nitric oxide (NO). 3. This review highlights recent findings on the importance of HDL in reducing atherosclerotic risk. We focus on the beneficial effects of HDL-induced NO release and how this relates to endothelial dysfunction and on the effect of HDL on vascular repair via endothelial progenitor cells.
Andrews
Karen L
KL
Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Moore
Xiao L
XL
Chin-Dusting
Jaye P F
JP
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D050197:Atherosclerosis / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000378:metabolism*; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006801:Humans; D008075:Lipoproteins, HDL / Q000494:pharmacology / Q000502:physiology*; D051379:Mice; D009569:Nitric Oxide / Q000096:biosynthesis*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism*; D013234:Stem Cells / Q000378:metabolism; D013927:Thrombosis / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D005343:Fibrinolytic Agents; D008075:Lipoproteins, HDL; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III